Earnings Feed
Start Free
BARRIER THERAPEUTICS INC·4

Apr 30, 6:52 PM ET

J P MORGAN PARTNERS GLOBAL INVESTORS CAYMAN II LP 4

4 · BARRIER THERAPEUTICS INC · Filed Apr 30, 2004

Insider Transaction Report

Form 4
Period: 2004-04-28
BARRIER THERAPEUTICS INCBTRX
JP MORGAN PARTNERS BHCA LP
10% Owner
Transactions
  • Conversion

    Common Stock

    2004-04-28+22,483→ 22,483 total(indirect: See Footnote)
  • Conversion

    Series B Convertible Preferred Stock

    2004-04-28−665,744→ 0 total(indirect: See Footnote)
    From: 2004-04-28→ Common Stock (332,872 underlying)
  • Conversion

    Series C Convertible Preferred Stock

    2004-04-28−65,370→ 0 total(indirect: See Footnote)
    From: 2004-04-28→ Common Stock (32,685 underlying)
  • Conversion

    Series C Convertible Preferred Stock

    2004-04-28−20,007→ 0 total(indirect: See Footnote)
    From: 2004-04-28→ Common Stock (10,003 underlying)
  • Conversion

    Common Stock

    2004-04-28+397,975→ 397,975 total(indirect: See Footnote)
  • Conversion

    Series B Convertible Preferred Stock

    2004-04-28−4,201,280→ 0 total
    From: 2004-04-28→ Common Stock (2,100,640 underlying)
  • Conversion

    Series B Convertible Preferred Stock

    2004-04-28−37,657→ 0 total(indirect: See Footnote)
    From: 2004-04-28→ Common Stock (18,828 underlying)
  • Conversion

    Series C Convertible Preferred Stock

    2004-04-28−740,321→ 0 total
    From: 2004-04-28→ Common Stock (370,160 underlying)
  • Conversion

    Series C Convertible Preferred Stock

    2004-04-28−7,310→ 0 total(indirect: See Footnote)
    From: 2004-04-28→ Common Stock (3,655 underlying)
  • Conversion

    Common Stock

    2004-04-28+55,380→ 55,380 total(indirect: See Footnote)
  • Conversion

    Series C Convertible Preferred Stock

    2004-04-28−130,207→ 0 total(indirect: See Footnote)
    From: 2004-04-28→ Common Stock (65,103 underlying)
  • Conversion

    Common Stock

    2004-04-28+2,470,800→ 2,470,800 total
  • Conversion

    Common Stock

    2004-04-28+201,635→ 201,635 total(indirect: See Footnote)
  • Conversion

    Series B Convertible Preferred Stock

    2004-04-28−337,900→ 0 total(indirect: See Footnote)
    From: 2004-04-28→ Common Stock (168,950 underlying)
  • Conversion

    Series B Convertible Preferred Stock

    2004-04-28−90,754→ 0 total(indirect: See Footnote)
    From: 2004-04-28→ Common Stock (45,377 underlying)
Footnotes (5)
  • [F1]The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors, L.P.
  • [F2]The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors (Cayman), L.P.
  • [F3]The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors A, L.P.
  • [F4]The amount shown represents the beneficial ownership of the Issuer's equity securities by J.P. Morgan Partners Global Investors (Cayman) II, L.P.
  • [F5]The Series B and Series C Convertible Preferred Stock is immediately exercisable. It has no expiration date. Upon the close of the Issuer's initial public offering, these shares were automatically converted into Common Stock of the Issuer. These shares are convertible on a two for one basis.

Documents

2 files